Detection of single nucleotide variants in circulating tumor DNA of patients with metastatic castration resistant prostate cancer
Roberto Pili, MD
Primary Investigator
Jessica MacLean
Primary Investigator
Overview
The purpose of this study is to investigate cell-free DNA in patients with metastatic castration-resistant prostate cancer receiving therapy with abiraterone or enzalutamide.
Description
The purpose of this study is to investigate cell-free DNA in patients with metastatic castration-resistant prostate cancer receiving therapy with abiraterone or enzalutamide.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
prostate cancer
-
Age: - 100 Years
-
Gender: All
Connect with a study center near you
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
